Press Releases
Date Title and Summary View
Jan 9, 2017 FDA discussions on sparsentan planned for January; RE-024 advancing with Phase 3 trial for the treatment of PKAN Preliminary Full-Year 2016 Revenue of Approximately $134 Million SAN DIEGO, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that, based on preliminary and unaudited financial data, the Company ...
Jan 4, 2017 SAN DIEGO, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced Elizabeth Reed has been appointed general counsel and corporate secretary, effective immediately. Ms. Reed will be responsible for overseeing the Company's general legal, intellectual property, government affairs and corporate compliance functions, reportin...
Dec 29, 2016 SAN DIEGO, Dec. 29, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 12, 2017 at 10:30 a.m. PT. A live webcast of the presentation will be available at http://ir.retrophi...
Nov 30, 2016 SAN DIEGO, Nov. 30, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the BMO Capital Markets Prescription for Success Healthcare Conference in New York City on Wednesday, December 14, 2016 at 10:30 a.m. ET. A live webcast of the presentation will be availabl...
Nov 19, 2016 Significant reduction of proteinuria compared to irbesartan Statistically significant difference in modified partial remission; complete remission also observed Further analysis supports sparsentan generally safe and well-tolerated SAN DIEGO, Nov. 19, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced additional resul...
Nov 10, 2016 SAN DIEGO , Nov. 10, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced it has reached an agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process for a Phase 3 clinical trial evaluating RE-024, the Company's novel investigational replacement therapy, for the treatment of p...
Nov 3, 2016 Positive top-line results from DUET announced in September; additional data to be presented at ASN Kidney Week 2016 Third quarter revenues increased 21 percent year-over-year SAN DIEGO, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today reported its third quarter 2016 financial results. Net product sales for the third qu...
Oct 21, 2016 SAN DIEGO, Oct. 21, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced that additional data from the Phase 2 DUET study of sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS) will be presented at the late-breaking High-Impact Clinical Trials oral session at the American Society of Nephrology (ASN) Kidney ...
Oct 20, 2016 SAN DIEGO, Oct. 20, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced it will report third quarter 2016 financial results on Thursday, November 3, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:...
Oct 6, 2016 SAN DIEGO, Oct. 06, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced Alvin Shih, M.D., will be stepping down from his position as executive vice president and head of research and development to become chief executive officer of a start-up biotechnology company. Dr. Shih will remain in his current role until October 31, 2016...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase